SCHEMBL99448

SCHEMBL99448

COc1ccc(C(=O)CCCC(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 1.00
NPC1 O15118 2/20 0.63
RAB9A P51151 1/20 0.63
HDAC8 Q9BY41 4/20 0.62
HDAC1 Q13547 4/20 0.62
MAPT P10636 1/20 0.62
KMT2A Q03164 1/20 0.60
ALDH1A1 P00352 1/20 0.59
CYP1A2 P05177 1/20 0.59
HPGD P15428 1/20 0.59
CYP2C19 P33261 1/20 0.59
HSD17B10 Q99714 1/20 0.59
MMP1 P03956 1/20 0.58
HDAC3 O15379 2/20 0.58
HDAC4 P56524 2/20 0.58
HDAC7 Q8WUI4 2/20 0.58
HDAC2 Q92769 2/20 0.58
HDAC10 Q969S8 2/20 0.58
HDAC11 Q96DB2 2/20 0.58
HDAC6 Q9UBN7 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413943 0.96 PDE4B (0.93) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL3383941 0.95 PDE4B (0.90) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL3104200 0.95 PDE4B (0.90) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL4082864 0.93 PDE4B (0.86) PDE4BNPC1RAB9AHDAC8HDAC1
Methoxyacetic Acid SCHEMBL7820069 0.92 PDE4B (0.85) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL3383272 0.90 PDE4B (0.82) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL503582 0.89 PDE4B (0.80) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL3171960 0.89 PDE4B (0.79) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL7995333 0.86 PDE4B (0.75) PDE4BNPC1RAB9AHDAC8HDAC1
SCHEMBL14960046 0.86 PDE4B (0.75) PDE4BNPC1RAB9AHDAC8HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
EP-1745004-B1 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2016-05-18 EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
US-9035085-B2 Aryl ketone compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2015-05-19 US claimed
US-20080167217-A1 aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, EMISPHERE TECHNOLOGIES, INC. (US) 2008-07-10 US claimed
EP-1745004-A4 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2007-05-09 EP claimed
EP-1745004-A2 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS Emisphere Technologies, Inc. (US) 2007-01-24 EP claimed
WO-2005117854-A2 ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2005-12-15 WO claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed
EP-3922267-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2021-12-15 EP disclosed
CN-112778117-A Method for synthesizing 4- (4-fluorobenzoyl) butyric acid and analogue thereof in continuous flow microreactor 江苏阿尔法药业有限公司 2021-05-11 CN disclosed
EP-3050576-B1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S (DK) 2021-03-31 EP disclosed
US-10960053-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2021-03-30 US disclosed
US-5149462-A Used as ferroelectric liquid crystal MITSUBISHI RAYON COMPANY LTD. (JP) 1992-09-22 US disclosed
EP-0409066-A2 Optically active compound for liquid crystal and its use MITSUBISHI RAYON COMPANY, LTD. (JP) 1991-01-23 EP disclosed
US-4839360-A ANTIDEPRESSANTS; NERVOUS AND PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS TANABE SEIYAKU CO., LTD. (JP) 1989-06-13 US disclosed
CN-87107226-A Lactam derivatives and preparation thereof 1988-06-29 CN disclosed
EP-0270093-A2 Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties TANABE SEIYAKU CO., LTD. (JP) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10960053-B2 PEGylated recombinant human growth hormone compounds GHRHR, GHITM, GHSR PDE4B 4386/4885NPC1 3435/4885RAB9A 3195/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 PDE4B 2823/4885NPC1 1607/4885RAB9A 3841/4885
US-20080167217-A1 aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, AKR1C3, AKR1C1, AKR1A1 PDE4B 3278/4885NPC1 21/4885RAB9A 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.